
Opinion|Videos|July 1, 2024
Duration of Therapy and Dosing Strategies in RCC
Author(s)Martin H. Voss, MD
An expert on non–clear cell renal cell carcinoma provides clinical insights on TKI dosing strategies and duration of therapy implications for IO-TKI combinations.
Advertisement
Episodes in this series

Video content above is prompted by the following question(s):
- In your experience, what is the optimal duration of treatment with lenvatinib in patients with advanced renal clear cell carcinoma?
- How do you monitor patients and make decisions around continuing or discontinuing treatment in clinical practice?
- When do you consider switching therapies versus dose reductions to maintain treatment duration?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















